Cipla Ltd.

BSE: CIPLA500087ISIN INE059A01026

Healthcare
Pharmaceuticals
BSE 100

Share price

₹1,400.10+7.90 (+0.57%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹1,539.25
52W low: ₹1,165.55
Off 52W high: -9.04%
1M return: +4.96%
3M return: -3.44%
6M return: +2.55%
1Y return: -6.88%
20D avg volume: 52,884
50 DMA: ₹1,368.24
200 DMA: ₹1,363.85

Key ratios Consolidated

Market cap: ₹1,13,110 Cr
Current price: ₹1,400.10
52W high / low: ₹1,539.25 / ₹1,165.55
Face value: ₹2.00
P/E: 39.63
P/B: 3.20
EPS (TTM): ₹35.33
Book value / share: ₹438.14
ROE: —
ROCE: 14.90%
Operating margin: —
Net margin: —
Debt / equity: 0.01
Net debt: ₹-760.25 Cr
Interest cover: 97.04
Dividend yield: 0.93%
Dividend / share (TTM): ₹13.00
Payout: 36.80%
Cash conversion cycle: 116.4 days

Financials

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	7,404	7,119	6,541	7,074	7,589	6,957	6,730	7,073	7,051	6,694	6,163	6,604
	151.16	210.90	148.16	206.34	268.95	258.56	289.46	221.61	190.61	160.19	249.33	184.63
	7,555	7,330	6,689	7,281	7,858	7,216	7,019	7,295	7,242	6,854	6,413	6,788
	6,378	6,248	5,982	6,112	6,005	5,446	5,515	5,378	5,453	5,243	5,153	5,120
	1,524	1,357	1,382	1,462	1,528	1,469	1,398	1,297	1,474	1,241	1,253	1,196
	1,313	1,252	1,285	1,249	892.98	1,025	1,024	913.23	814.59	1,100	738.96	927.21
	1,475	1,497	1,414	1,325	1,315	1,312	1,233	1,198	1,208	1,194	1,084	1,068
	16.74	17.03	13.13	14.03	13.18	14.05	14.02	14.64	15.40	17.95	17.59	30.10
	344.86	304.24	382.92	278.35	296.99	252.72	308.73	279.80	271.74	246.68	288.34	233.43
	1,908	1,762	1,923	1,862	1,882	1,696	1,770	1,622	1,675	1,591	1,713	1,569
	1,177	1,082	707.06	1,169	1,854	1,770	1,504	1,916	1,789	1,611	1,259	1,669
	0.00	0.00	0.00	-275.91	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-194.82
	1,177	1,082	707.06	893.11	1,854	1,770	1,504	1,916	1,789	1,611	1,259	1,474
	320.82	294.83	156.95	218.55	500.46	477.88	279.28	332.37	483.04	435.07	324.86	405.30
	851.51	785.55	542.51	674.25	1,353	1,292	1,214	1,575	1,305	1,175	931.87	1,068
	10.86	9.77	6.87	8.37	16.73	16.07	15.13	19.45	16.13	14.58	11.63	13.08
Key metrics
	1,539	1,403	1,103	1,185	2,164	2,037	1,827	2,211	2,076	1,876	1,565	1,737
	20.80%	19.70%	16.90%	16.80%	28.50%	29.30%	27.10%	31.30%	29.40%	28.00%	25.40%	26.30%
	11.50%	11.00%	8.30%	9.50%	17.80%	18.60%	18.00%	22.30%	18.50%	17.60%	15.10%	16.20%
	3.30%	—	2.00%	—	5.50%	—	4.80%	—	—	—	—	—
	-2.40%	2.30%	-2.80%	0.00%	7.60%	3.90%	9.20%	7.10%	—	—	—	—
	-37.10%	-39.20%	-55.30%	-57.20%	3.70%	9.90%	30.30%	47.40%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18
Income statement
	28,139	28,163	27,548	25,774	22,753	21,763	19,160	17,132	16,362	15,219
	716.56	882.01	861.87	746.57	475.45	280.91	265.99	344.20	476.57	357.65
	28,855	29,045	28,409	26,521	23,229	22,044	19,426	17,476	16,839	15,577
	24,720	23,545	21,589	20,624	19,008	18,369	16,136	15,298	14,760	13,830
	5,725	5,842	5,410	5,221	5,520	5,533	4,886	4,377	4,285	4,497
	5,098	4,451	3,851	3,536	2,829	3,687	2,658	1,859	1,452	1,174
	5,711	5,366	4,833	4,310	3,830	3,530	3,252	3,027	2,857	2,690
	60.93	54.39	62.01	89.88	109.54	106.35	160.70	197.36	168.43	114.23
	1,310	1,211	1,107	1,051	1,172	1,052	1,068	1,175	1,326	—
	7,456	7,364	6,658	6,353	5,644	5,185	4,303	4,908	4,624	4,264
	4,135	5,500	6,821	5,897	4,221	3,675	3,290	2,178	2,079	1,747
	-275.91	-275.91	0.00	-194.82	-182.42	-182.12	0.00	0.00	0.00	-77.52
	3,859	5,224	6,821	5,702	4,038	3,493	3,290	2,178	2,079	1,669
	991.15	1,354	1,530	1,547	1,203	933.80	888.76	631.20	569.53	250.11
	2,854	3,862	5,269	4,154	2,833	2,547	2,389	1,500	1,492	1,419
	35.87	48.03	65.29	51.05	34.72	31.20	29.82	19.19	18.97	—
Key metrics
	5,231	6,489	7,990	6,843	5,320	4,652	4,518	3,550	3,574	1,784
	18.59%	23.00%	29.00%	26.50%	23.40%	21.40%	23.60%	20.70%	21.80%	11.70%
	10.14%	13.70%	19.10%	16.10%	12.50%	11.70%	12.50%	8.80%	9.10%	9.30%
	—	14.90%	21.60%	—	—	—	—	—	—	—
	-0.74%	2.20%	6.90%	13.30%	4.50%	13.60%	11.80%	4.70%	7.50%	—
	-47.48%	-26.70%	26.90%	46.60%	11.20%	6.60%	59.30%	0.50%	5.10%	—
	—	2,341	3,843	—	—	—	—	—	—	—
	—	1.02	0.95	—	—	—	—	—	—	—
	—	0.01	0.00	—	—	—	—	—	—	—
	—	-760.25	-496.59	—	—	—	—	—	—	—
	—	116.4	110.2	—	—	—	—	—	—	—
Balance sheet
	—	42,496	37,387	—	—	—	—	—	—	—
	—	24,146	23,249	—	—	—	—	—	—	—
	—	1,018	588.69	—	—	—	—	—	—	—
	—	5,620	5,506	—	—	—	—	—	—	—
	—	6,597	5,642	—	—	—	—	—	—	—
	—	1,459	1,055	—	—	—	—	—	—	—
	—	6,040	5,262	—	—	—	—	—	—	—
	—	3,230	2,837	—	—	—	—	—	—	—
	—	7,014	5,484	—	—	—	—	—	—	—
	—	257.97	92.10	—	—	—	—	—	—	—
	—	140.50	80.12	—	—	—	—	—	—	—
	—	117.47	11.98	—	—	—	—	—	—	—
	—	34,520	31,289	—	—	—	—	—	—	—
Cash flow
	—	3,940	5,005	—	—	—	—	—	—	—
	—	-2,326	-3,691	—	—	—	—	—	—	—
	—	-1,234	-1,293	—	—	—	—	—	—	—
	—	1,599	1,162	—	—	—	—	—	—	—

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	5,067	5,078	4,210	4,498	5,226	5,046	4,798	4,971	4,775	4,501	4,037	4,381
	147.56	242.75	180.22	416.70	254.66	271.07	293.37	188.69	289.14	213.52	538.61	168.98
	5,215	5,320	4,390	4,915	5,480	5,317	5,091	5,160	5,064	4,715	4,575	4,550
	4,153	4,167	3,868	3,934	3,847	3,573	3,630	3,455	3,486	3,284	3,351	3,170
	1,125	1,039	965.58	1,004	1,005	1,018	923.60	940.73	974.92	803.59	517.24	677.74
	636.72	651.15	763.51	746.64	530.39	547.43	464.76	475.64	544.27	572.08	467.43	537.32
	881.41	914.96	869.24	822.93	840.01	818.30	784.93	761.45	744.58	763.91	662.15	648.22
	5.92	5.68	6.74	4.03	2.65	5.88	3.49	3.55	3.00	5.07	5.45	9.06
	189.29	169.39	218.11	153.33	141.30	145.69	147.70	142.62	145.71	137.86	136.81	135.02
	1,403	1,366	1,397	1,327	1,304	1,182	1,313	1,176	1,174	1,080	1,385	1,012
	1,062	1,154	522.48	980.54	1,633	1,744	1,461	1,704	1,578	1,430	1,224	1,381
	0.00	0.00	0.00	-244.37	0.00	0.00	294.66	—	—	—	—	—
	1,062	1,154	522.48	736.17	1,633	1,744	1,756	1,704	1,578	1,430	1,224	1,381
	275.40	291.46	137.84	119.29	422.81	440.82	270.15	266.20	400.31	374.51	242.21	363.00
	787.03	862.16	384.64	616.88	1,211	1,303	1,485	1,438	1,178	1,056	1,038	1,114
	9.74	10.67	4.76	7.64	14.99	16.13	18.39	17.81	14.59	13.08	12.16	12.61
Key metrics
	1,258	1,329	747.33	893.53	1,777	1,896	1,907	1,851	1,727	1,573	1,366	1,525
	24.80%	26.20%	17.80%	19.90%	34.00%	37.60%	39.70%	37.20%	36.20%	35.00%	33.90%	34.80%
	15.50%	17.00%	9.10%	13.70%	23.20%	25.80%	31.00%	28.90%	24.70%	23.50%	25.70%	25.40%
	3.00%	—	1.50%	—	4.90%	—	5.40%	—	—	—	—	—
	-3.00%	0.60%	-12.30%	-9.50%	9.40%	12.10%	18.90%	13.50%	—	—	—	—
	-35.00%	-33.80%	-74.10%	-57.10%	2.70%	23.40%	43.00%	29.10%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18
Income statement
	18,853	18,980	19,045	16,574	15,791	13,092	13,901	12,659	12,374	11,445
	987.23	1,123	984.72	1,071	456.79	666.70	230.28	892.85	577.52	334.88
	19,840	20,103	20,030	17,645	16,247	13,758	14,131	13,552	12,952	11,780
	16,121	15,222	13,855	12,698	12,621	10,212	10,780	10,588	10,459	9,791
	4,133	3,992	3,643	2,617	3,503	2,768	3,262	2,999	3,112	3,303
	2,798	2,588	2,057	2,360	1,993	2,851	1,848	1,363	1,259	1,064
	3,489	3,350	3,055	2,644	2,377	1,729	2,039	1,911	1,840	1,786
	22.37	19.30	15.11	20.25	27.02	26.93	45.07	36.05	16.97	11.90
	730.12	658.43	573.89	587.59	595.91	460.01	556.11	599.78	569.72	529.61
	5,493	5,210	4,742	4,364	3,919	2,906	3,040	3,722	3,524	3,308
	3,719	4,880	6,174	4,947	3,626	3,546	3,351	2,964	2,493	1,989
	-244.37	-244.37	294.66	—	-185.90	—	—	—	—	-77.52
	3,475	4,636	6,469	4,947	3,441	3,546	3,351	2,964	2,493	1,911
	823.99	1,121	1,311	1,233	971.01	856.84	882.38	646.14	604.42	442.88
	2,651	3,515	5,158	4,077	2,513	2,958	2,468	2,318	1,888	1,469
	32.81	43.52	63.87	46.01	30.61	33.34	30.61	28.76	23.45	—
Key metrics
	4,227	5,314	7,058	5,555	4,063	4,033	3,952	3,600	3,080	2,453
	22.42%	28.00%	37.10%	33.50%	25.70%	30.80%	28.40%	28.40%	24.90%	21.40%
	14.06%	18.50%	27.10%	24.60%	15.90%	22.60%	17.80%	18.30%	15.30%	12.80%
	—	13.40%	20.00%	—	—	—	—	—	—	—
	-5.93%	-0.30%	14.90%	5.00%	20.60%	-5.80%	9.80%	2.30%	8.10%	—
	-51.25%	-31.80%	26.50%	62.20%	-15.00%	19.80%	6.50%	22.80%	28.60%	—
	—	2,051	2,730	—	—	—	—	—	—	—
	—	0.81	0.64	—	—	—	—	—	—	—
	—	0.00	0.00	—	—	—	—	—	—	—
	—	-238.20	-82.74	—	—	—	—	—	—	—
	—	109.4	107.0	—	—	—	—	—	—	—
Balance sheet
	—	38,493	35,566	—	—	—	—	—	—	—
	—	17,912	18,369	—	—	—	—	—	—	—
	—	248.80	82.74	—	—	—	—	—	—	—
	—	3,397	3,860	—	—	—	—	—	—	—
	—	4,354	3,607	—	—	—	—	—	—	—
	—	1,041	675.11	—	—	—	—	—	—	—
	—	3,782	3,508	—	—	—	—	—	—	—
	—	2,062	1,884	—	—	—	—	—	—	—
	—	3,872	3,183	—	—	—	—	—	—	—
	—	10.60	0.00	—	—	—	—	—	—	—
	—	10.60	0.00	—	—	—	—	—	—	—
	—	0.00	0.00	—	—	—	—	—	—	—
	—	34,201	32,099	—	—	—	—	—	—	—
Cash flow
	—	2,832	3,301	—	—	—	—	—	—	—
	—	-1,344	-2,309	—	—	—	—	—	—	—
	—	-1,322	-1,074	—	—	—	—	—	—	—
	—	780.69	571.06	—	—	—	—	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: +6.32%
Sales CAGR 5Y: +6.43%
Profit CAGR 3Y: +11.83%
Profit CAGR 5Y: +7.33%
Sales YoY (TTM): -5.93%
Profit YoY (TTM): -51.25%

Consolidated

Sales CAGR 3Y: +7.37%
Sales CAGR 5Y: +8.01%
Profit CAGR 3Y: +10.88%
Profit CAGR 5Y: +10.09%
Sales YoY (TTM): -0.74%
Profit YoY (TTM): -47.48%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 29.21%

Quarter	September 2026	June 2026	March 2026
Promoter %	29.21%	29.22%	29.22%

Holder	Type	Holding	Previous	Change
Yusuf Khwaja Hamied	Promoter	18.68%	18.69%	-0.01%
LICI ULIP-GROWTH FUND	Public	9.59%	9.75%	-0.16%
SOPHIE AHMED	Promoter Group	5.71%	5.71%	0.00%
HDFC MUTUAL FUND - HDFC FOCUSED FUND	Public	4.03%	—	—
M K HAMIED	Promoter	3.46%	3.46%	0.00%
SBI ELSS TAX SAVER FUND	Public	3.41%	—	—
ICICI PRUDENTIAL NIFTY50 EQUAL WEIGHT INDEX FUND	Public	2.89%	—	—
NIPPON LIFE INDIA TRUSTEE LTD-A/C NIPPON INDIA ARB	Public	2.03%	1.96%	+0.07%
PARAG PARIKH ARBITRAGE FUND	Public	1.86%	1.87%	-0.01%
DSP FLEXI CAP FUND	Public	1.82%	—	—
NPS TRUST -A/C LIC PENSION FUND LIMITED APY FUND S	Public	1.79%	—	—
Kamil Hamied	Promoter Group	1.36%	1.36%	0.00%
GOVERNMENT PENSION FUND GLOBAL	Public	1.23%	1.30%	-0.07%
VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND	Public	1.05%	1.04%	+0.01%
VANGUARD EMERGING MARKETS STOCK INDEX FUND, A SERI	Public	1.01%	—	—

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%

Filings & corporate actions

Recent announcements

Appointment of Mr Vikram Janakiraman, as the Global Chief Technical Operating Officer, designated as a Senior Management Personnel of the Company, with effect from 7th December, 2026.4 Nov 2026 · Company Update / Change in Management
Please find attached newspaper publication regarding opening of special window for re-lodgement of transfer and dematerialisation of physical shares3 Nov 2026 · Company Update / Newspaper Publication
Please find enclosed Earnings Call Transcript - Q2FY2730 Oct 2026 · Company Update / Earnings Call Transcript
In compliance with the provisions of Regulation 30 of SEBI (LODR) Regulations, 2015, we hereby notify that the Operations and Administrative Committee of the Company on 29th October, 2026 ....29 Oct 2026 · Company Update / Allotment of ESOP / ESPS
Please find enclosed newspaper intimation for financial results for the quarter and half year ended 30th September, 2026.28 Oct 2026 · Company Update / Newspaper Publication
Pursuant to Regulation 30 read with Part A of Schedule III and Regulation 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the audio recording of the ....27 Oct 2026 · Company Update / Analyst / Investor Meet
Please find intimation in relation to grant of ESOS and ESAR.27 Oct 2026 · Company Update / General
Please find enclosed the intimation for Appointment of Ms Rashmi Joshi as an additional and independent director of the Company w.e.f. 27th October, 2026 for a period of 5 years.27 Oct 2026 · Company Update / Change in Directorate
Please find enclosed the intimation for appointment of Ms Rashmi Joshi as an additional and independent director of the company w.e.f. 27th October, 2026 for a period of 5 years.27 Oct 2026 · Board Meeting / Outcome of Board Meeting
Please find enclosed investor presentation.27 Oct 2026 · Company Update / Investor Presentation
Please find enclosed press release for Q2FY27 financial results.27 Oct 2026 · Company Update / Press Release / Media Release
Please find enclosed the financial results for the quarter and half year ended 30th September, 2026.27 Oct 2026 · Result / Financial Results
Please find enclosed disclosure.23 Oct 2026 · Company Update / General
Certificate under Regulation 74 (5) of SEBI (DP) Regulations, 201815 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Please find enclosed intimation for Earnings Conference Call.13 Oct 2026 · Company Update / Analyst / Investor Meet
Cipla Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/10/2026 ,inter alia, to consider and approve the unaudited standalone and consolidated ....28 Sep 2026 · Board Meeting / Board Meeting
In terms of Regulation 30 of SEBI (LODR) Regulations, 2015, we hereby notify that the Operations and Administrative Committee of the Company on 24th September, 2026 has allotted 12,168 ....24 Sep 2026 · Company Update / Allotment of ESOP / ESPS
Please find enclosed disclosure relating to the Change in SMP.22 Sep 2026 · Company Update / Change in Management
Please find enclosed disclosure on ESG Rating.18 Sep 2026 · Company Update / General
Please find enclosed press release titled ''Cipla Announces Exclusive Partnership with Qilu Pharmaceutical for the Licensing and Supply of Biosimilar to Keytruda (Pembrolizumab) in the US''3 Sep 2026 · Company Update / Press Release / Media Release
Please find enclosed disclosure3 Sep 2026 · Company Update / General
Please find attached newspaper publication regarding opening of special window for re-lodgement of transfer and dematerialisation of physical shares2 Sep 2026 · Company Update / Newspaper Publication
Please find enclosed press release titled "Cipla and SBP Group sign exclusive licensing agreement for potential best-in-class HER2 bispecific ADC Rolditamig Deuderuxtecan (TQB2102)"31 Aug 2026 · Company Update / Press Release / Media Release
Please find enclosed disclosure.28 Aug 2026 · Company Update / General
Please find enclosed disclosure.27 Aug 2026 · Company Update / Restructuring
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we herein mention the schedule of Analyst / ....27 Aug 2026 · Company Update / Analyst / Investor Meet
In terms of regulation 30 of SEBI (LODR) Regulations, 2015, we hereby notify that the Operations and Admisnistrative Committee of the Company on 26th August, 2026 has allotted 5,281 fully ....26 Aug 2026 · Company Update / Allotment of ESOP / ESPS
Please find enclosed disclosure25 Aug 2026 · Company Update / General
Cipla has informed the exchange about receipt of order from Hon''ble NCLT, Mumbai Bench19 Aug 2026 · Company Update / Scheme of Arrangement
Please find attached disclosure on ESG Ratings.11 Aug 2026 · Company Update / General
Please find enclosed intimation.4 Aug 2026 · Company Update / General
In compliance with the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirments) Regulations, 2015, we hereby notify that the Operations and Administrative Committee ....31 Jul 2026 · Company Update / Allotment of ESOP / ESPS
Please find enclosed disclosure27 Jul 2026 · Company Update / General
Please find enclosed Earnings Call Transcript - Q1FY2727 Jul 2026 · Company Update / Earnings Call Transcript
Please find attached newspaper intimation for unaudited financial results for the quarter ended 30th June, 2026.24 Jul 2026 · Company Update / Newspaper Publication
Pursuant to Regulation 30 read with Part A of Schedule III and Regulation 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the audio recording of the ....23 Jul 2026 · Company Update / Analyst / Investor Meet
Please find enclosed disclosure23 Jul 2026 · Company Update / General
Please find enclosed disclosure23 Jul 2026 · Company Update / General
Please find enclosed disclosure23 Jul 2026 · Company Update / General
Please find enclosed disclosure23 Jul 2026 · Company Update / General

Corporate actions

Purpose	Ex date	Record date	Payment date
Final Dividend - Rs. - 13.0000	5 Jun 2026	5 Jun 2026	—
Special Dividend - Rs. - 3.0000	27 Jun 2025	27 Jun 2025	—
Final Dividend - Rs. - 13.0000	27 Jun 2025	27 Jun 2025	—
Final Dividend - Rs. - 13.0000	2 Aug 2024	2 Aug 2024	—

Board meetings

27 Oct 2026 Board Meeting - Financial Results
23 Jul 2026 Board Meeting - Financial Results